Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDSET 2: KarXT + KarX-EC for Cognitive Impairment in Mild to Moderate Alzheimer's Disease
jRCT2031250435Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing KarXT + KarX-EC with Placebo / KarXT + KarX-EC (OLE) (2 arms). Primary endpoints: ADAS-Cog11 change from baseline at Week 24 and CIBIC+ at Week 24. Started Dec 2025; status: recruiting.
02
Drugs
xanomelineKarX-EC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031250435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250435.